300204 舒泰神
已收盘 04-17 15:00:00
资讯
新帖
简况
舒泰神：继续推进注射用STSP-0601附条件批准上市工作
证券之星 · 04-08
舒泰神：继续推进注射用STSP-0601附条件批准上市工作
舒泰神（300204）披露向特定对象发行股票募集说明书（注册稿），4月3日股价下跌4.28%
证券之星 · 04-03
舒泰神（300204）披露向特定对象发行股票募集说明书（注册稿），4月3日股价下跌4.28%
舒泰神：公司暂无研发方向相关合作
证券之星 · 04-03
舒泰神：公司暂无研发方向相关合作
舒泰神不超12.53亿定增获深交所通过 国金证券建功
中金财经 · 04-01
舒泰神不超12.53亿定增获深交所通过 国金证券建功
3月27日舒泰神（300204）龙虎榜数据：机构净买入698.54万元，北向资金净买入7015.15万元
证券之星 · 03-27
3月27日舒泰神（300204）龙虎榜数据：机构净买入698.54万元，北向资金净买入7015.15万元
异动快报：舒泰神（300204）3月27日13点33分触及涨停板
证券之星 · 03-27
异动快报：舒泰神（300204）3月27日13点33分触及涨停板
舒泰神（300204）披露拟向银行申请贷款并提供抵押反担保的进展公告，3月25日股价上涨1.2%
证券之星 · 03-25
舒泰神（300204）披露拟向银行申请贷款并提供抵押反担保的进展公告，3月25日股价上涨1.2%
舒泰神：公司2025年年度报告披露时间符合相关规定
证券之星 · 03-24
舒泰神：公司2025年年度报告披露时间符合相关规定
舒泰神：已按发补通知要求补充提交相关材料
证券之星 · 03-17
舒泰神：已按发补通知要求补充提交相关材料
舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料
证券之星 · 03-11
舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料
3月3日舒泰神跌5.10%，景顺长城医疗健康混合A基金重仓该股
证券之星 · 03-03
3月3日舒泰神跌5.10%，景顺长城医疗健康混合A基金重仓该股
舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料
证券之星 · 02-26
舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料
舒泰神：香塘集团完成减持477.77万股，持股比例降至4.69%
证券日报 · 02-11
舒泰神：香塘集团完成减持477.77万股，持股比例降至4.69%
舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料
证券之星 · 02-10
舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料
2月10日舒泰神现1笔折价14.8%的大宗交易 合计成交2299.89万元
证券之星 · 02-10
2月10日舒泰神现1笔折价14.8%的大宗交易 合计成交2299.89万元
股市必读：舒泰神（300204）2月5日董秘有最新回复
证券之星 · 02-06
股市必读：舒泰神（300204）2月5日董秘有最新回复
舒泰神：注射用STSP-0601III期临床试验正在正常推进中
证券之星 · 02-05
舒泰神：注射用STSP-0601III期临床试验正在正常推进中
股市必读：舒泰神（300204）1月30日董秘有最新回复
证券之星 · 02-02
股市必读：舒泰神（300204）1月30日董秘有最新回复
舒泰神：公司生产经营活动正常
证券之星 · 01-30
舒泰神：公司生产经营活动正常
舒泰神最新公告：预计2025年净利润亏损6981.35万元-8532.76万元
证券之星 · 01-28
舒泰神最新公告：预计2025年净利润亏损6981.35万元-8532.76万元
暂无数据
公司概况
公司名称：
舒泰神(北京)生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-15
主营业务：
舒泰神(北京)生物制药股份有限公司的主营业务是生物药物的研发、生产和营销。公司的主要产品是创新生物药物苏肽生（注射用鼠神经生长因子）、特色品种舒泰清（复方聚乙二醇电解质散（IV））。
发行价格：
52.50
{"stockData":{"symbol":"300204","market":"SZ","secType":"STK","nameCN":"舒泰神","latestPrice":30.33,"timestamp":1776409413000,"preClose":31.51,"halted":0,"volume":45878144,"delay":0,"changeRate":-0.0374,"floatShares":454000000,"shares":478000000,"eps":-0.3478,"marketStatus":"已收盘","change":-1.18,"latestTime":"04-17 15:00:00","open":30.94,"high":31.36,"low":30.01,"amount":1396000000,"amplitude":0.0428,"askPrice":30.34,"askSize":60,"bidPrice":30.33,"bidSize":1650,"shortable":0,"etf":0,"ttmEps":-0.3478,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":31.51,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":34.66,"lowLimit":28.36,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":477772555,"isCdr":false,"pbRate":17.29,"roa":"--","roe":"--","epsLYR":-0.3,"committee":0.769253,"marketValue":14491000000,"turnoverRate":0.1011,"status":1,"floatMarketCap":13760000000},"requestUrl":"/m/hq/s/300204/tweets","defaultTab":"tweets","newsList":[{"id":"2625436941","title":"舒泰神：继续推进注射用STSP-0601附条件批准上市工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625436941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625436941?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:51","pubTimestamp":1775652681,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神04月07日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，贵公司用于治疗血友病的独家创新药 STSP-0601 上市申请已获受理，并被纳入优先审评，预计 2026年 有望获批上市。公司前期已按照发补通知要求组织相关部门落实并补充提交了相关材料，继续推进注射用STSP-0601附条件批准上市工作。公司重视BD工作的开展，并有相应人员进行推动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800036391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300204","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624213668","title":"舒泰神（300204）披露向特定对象发行股票募集说明书（注册稿），4月3日股价下跌4.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624213668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624213668?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:04","pubTimestamp":1775225063,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，舒泰神报收于31.52元，较前一交易日下跌4.28%，最新总市值为150.59亿元。该股当日开盘31.14元，最高33.19元，最低31.14元，成交额达21.3亿元，换手率为14.66%。近日，舒泰神（北京）生物制药股份有限公司披露《2025年度向特定对象发行股票募集说明书（注册稿）》。公告显示，公司拟向特定对象发行股票，募集资金总额不超过12.53亿元，用于创新药物研发项目及补充流动资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0239","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624465853","title":"舒泰神：公司暂无研发方向相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624465853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624465853?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:00","pubTimestamp":1775199644,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：1. 药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。请问贵司在管线研发中，是否与药石科技有合作？未来是否有计划在早期化合物发现、工艺开发或商业化生产层面开展合作？舒泰神回复：您好！公司暂无研发方向相关合作。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0239","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624566325","title":"舒泰神不超12.53亿定增获深交所通过 国金证券建功","url":"https://stock-news.laohu8.com/highlight/detail?id=2624566325","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624566325?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:42","pubTimestamp":1775014922,"startTime":"0","endTime":"0","summary":"中国经济网北京4月1日讯 舒泰神 昨晚披露关于收到《关于舒泰神(北京)生物制药股份有限公司申请向特定对象发行股票的审核中心意见告知函》的公告称，舒泰神于2026年03月31日收到深圳证券交易所上市审核中心出具的《关于舒泰神(北京)生物制药股份有限公司申请向特定对象发行股票的审核中心意见告知函》。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/01/20260401991506.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/01/20260401991506.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260401/32117880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0201","BK0188","BK0028","300204","600109","BK0239","BK0276","BK0012","BK0046","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622122844","title":"3月27日舒泰神（300204）龙虎榜数据：机构净买入698.54万元，北向资金净买入7015.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622122844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622122844?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:17","pubTimestamp":1774603046,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年3月27日公布的交易公开信息显示，舒泰神因日涨幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年3月27日收盘，舒泰神报收于27.76元，上涨20.02%，涨停，换手率12.28%，成交量55.71万手，成交额14.42亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入698.54万元，北向资金合计净买入7015.15万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700035999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622081755","title":"异动快报：舒泰神（300204）3月27日13点33分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2622081755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622081755?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:35","pubTimestamp":1774589728,"startTime":"0","endTime":"0","summary":"证券之星3月27日盘中消息，13点33分舒泰神触及涨停板。其所属行业化学制药目前上涨。该股为创新药，医药，新冠病毒防治概念热股，当日创新药概念上涨4.52%，医药概念上涨3.48%，新冠病毒防治概念上涨2.29%。3月26日的资金流向数据方面，主力资金净流出443.08万元，占总成交额2.14%，游资资金净流出93.67万元，占总成交额0.45%，散户资金净流入536.75万元，占总成交额2.59%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700024711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300204","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072208","title":"舒泰神（300204）披露拟向银行申请贷款并提供抵押反担保的进展公告，3月25日股价上涨1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072208","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622072208?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:33","pubTimestamp":1774449194,"startTime":"0","endTime":"0","summary":"截至2026年3月25日收盘，舒泰神报收于23.6元，较前一交易日上涨1.2%，最新总市值为112.75亿元。舒泰神（北京）生物制药股份有限公司于2026年3月25日公告，公司与北京亦庄国际融资担保有限公司签订《抵押反担保合同》，以自有房产及土地使用权为公司向交通银行股份有限公司北京自贸试验区支行申请的2,000万元流动资金贷款提供反担保。本次担保后，公司对亦庄担保的实际担保发生额为2,600万元，已用担保额度达23,600万元，剩余可用额度6,400万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500044393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","161121","BK0239","300204","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621037627","title":"舒泰神：公司2025年年度报告披露时间符合相关规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2621037627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621037627?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:36","pubTimestamp":1774323388,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神03月23日在投资者关系平台上答复投资者关心的问题。公司2025年年度报告披露时间符合《深圳证券交易所创业板股票上市规则》第6.1.2条规定，“上市公司应当在每个会计年度结束之日起四个月内披露年度报告”。公司生产经营活动正常，不存在不能按期披露定期报告的情况，不存在前期已披露的业绩预告数据变更情况，与会计师事务所不存在就2025年年度报告审计的分歧情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400016359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427821","title":"舒泰神：已按发补通知要求补充提交相关材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427821?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:48","pubTimestamp":1773751706,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)03月17日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，不是说80个工作日内要提交吗？都满80个工作日了，怎么还没提交0601的补充资料上去？舒泰神回复：您好！感谢您对公司研发项目的关注。公司已按照发补通知要求组织相关部门落实并补充提交了相关材料，继续推进注射用STSP-0601附条件批准上市工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","300204","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618947128","title":"舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947128","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618947128?lang=zh_cn&edition=full","pubTime":"2026-03-11 20:48","pubTimestamp":1773233290,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：0601的补充材料还没有正式提交绐CDE么舒泰神回复：您好！公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料，继续推进注射用STSP-0601附条件批准上市工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100037191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","300204","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616317212","title":"3月3日舒泰神跌5.10%，景顺长城医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616317212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616317212?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:52","pubTimestamp":1772527956,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日舒泰神跌5.10%创60日新低，收盘报24.55元，换手率2.94%，成交量13.35万手，成交额3.34亿元。重仓舒泰神的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为景顺长城基金的景顺长城医疗健康混合A。景顺长城医疗健康混合A目前规模为2.92亿元，最新净值0.6855，较上一交易日下跌2.68%，近一年上涨10.19%。该公募基金现任基金经理为乔海英。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","300204","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614804148","title":"舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2614804148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614804148?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:52","pubTimestamp":1772110379,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问0601的补充材料递交了么舒泰神回复：您好！感谢您对公司研发项目的关注。公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料，继续推进注射用STSP-0601附条件批准上市工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600035443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300204","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610895885","title":"舒泰神：香塘集团完成减持477.77万股，持股比例降至4.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610895885","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610895885?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:07","pubTimestamp":1770815220,"startTime":"0","endTime":"0","summary":"证券日报网讯 2月11日，舒泰神发布公告称，公司原持股5%以上股东香塘集团通过大宗交易于2025年12月12日至2026年2月10日合计减持477.77万股，占总股本1%，减持计划已实施完毕，香塘集团及其一致行动人合计持股比例降至4.69%。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-11/doc-inhmnhqz7433343.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-11/doc-inhmnhqz7433343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","300204","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610434640","title":"舒泰神：公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2610434640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610434640?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:51","pubTimestamp":1770727903,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司是否确发补材料不涉及影响股价波动的重大技术问题而只是常规问题？舒泰神回复：您好！感谢您对公司研发项目的关注。公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料，继续推进注射用STSP-0601附条件批准上市工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000036792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0239","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610648675","title":"2月10日舒泰神现1笔折价14.8%的大宗交易 合计成交2299.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610648675","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610648675?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:22","pubTimestamp":1770715332,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日舒泰神发生大宗交易，交易数据如下：大宗交易成交价格23.43元，相对当日收盘价折价14.8%，成交98.16万股，成交金额2299.89万元，买方营业部为中信证券股份有限公司江苏分公司，卖方营业部为东吴证券股份有限公司太仓上海东路证券营业部。近三个月该股共发生6笔大宗交易，合计成交4.78万手，折价成交6笔。截至2026年2月10日收盘，舒泰神报收于27.5元，上涨1.55%，换手率6.1%，成交量27.66万手，成交额7.63亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000027808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","300204","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609983588","title":"股市必读：舒泰神（300204）2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609983588","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609983588?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:19","pubTimestamp":1770311948,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，舒泰神报收于27.45元，上涨0.96%，换手率6.03%，成交量27.35万手，成交额7.57亿元。注射用STSP-0601在伴抑制物血友病A或B患者出血按需治疗方向登记号为CTR20250843的III期临床试验正在正常推进中。有关研发项目进展，敬请关注CDE平台公示、后续定期报告及项目进展公告。当日关注点来自交易信息汇总：2月5日主力资金净流入1415.69万元，呈现明显吸筹迹象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300204","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609370643","title":"舒泰神：注射用STSP-0601III期临床试验正在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2609370643","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609370643?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:48","pubTimestamp":1770295711,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)02月05日在投资者关系平台上答复投资者关心的问题。投资者提问：广生堂今天公告完成三期临床全部受试者入组，贵司0601受试者是不是还没招满人？舒泰神回复：您好！注射用STSP-0601在伴抑制物血友病A或B患者出血按需治疗方向登记号为CTR20250843的III期临床试验正在正常推进中。有关研发项目进展，敬请关注CDE平台公示、后续定期报告及项目进展公告。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500037506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608885030","title":"股市必读：舒泰神（300204）1月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608885030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608885030?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:49","pubTimestamp":1769968148,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，舒泰神报收于25.66元，上涨0.63%，换手率3.36%，成交量15.26万手，成交额3.95亿元。董秘最新回复投资者： 0601资料准备的怎么样了？什么时候提交董秘： 您好！公司生产经营活动正常，并通过加强已上市品种的营销工作、银行贷款及推动定增等多途径增强现金储备。公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料，继续推进注射用STSP-0601附条件批准上市工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607094591","title":"舒泰神：公司生产经营活动正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2607094591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607094591?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:33","pubTimestamp":1769758393,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神01月30日在投资者关系平台上答复投资者关心的问题。公司生产经营活动正常，并通过加强已上市品种的营销工作、银行贷款及推动定增等多途径增强现金储备。公司与银行签订借款合同是为了保障公司日常生产经营及补充公司流动资金需求，预期会对公司生产经营产生积极的影响，有利于公司的平稳发展。公司2025年度向特定对象发行股票事项正在有序推进中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000020792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606799365","title":"舒泰神最新公告：预计2025年净利润亏损6981.35万元-8532.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606799365","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606799365?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:52","pubTimestamp":1769590366,"startTime":"0","endTime":"0","summary":"舒泰神(300204.SZ)公告称，舒泰神预计2025年归属于上市公司股东的净利润为-8532.76万元至-6981.35万元，上年同期为-14484.26万元。业绩变动原因：苏肽生销售收入及销量略有增长；舒泰清收入下降，公司正多渠道拓展舒泰清及聚乙二醇类新产品营销。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800028393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776432579725,"stockEarnings":[{"period":"1week","weight":0.0918},{"period":"1month","weight":0.2529},{"period":"3month","weight":0.1048},{"period":"6month","weight":-0.2103},{"period":"1year","weight":3.0397},{"period":"ytd","weight":0.1534}],"compareEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.0014},{"period":"3month","weight":-0.0113},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.238},{"period":"ytd","weight":0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"舒泰神(北京)生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"46538人(较上一季度增加46.97%)","perCapita":"9748股","listingDate":"2011-04-15","address":"北京市大兴区北京经济技术开发区经海二路36号","registeredCapital":"47777万元","survey":" 舒泰神(北京)生物制药股份有限公司的主营业务是生物药物的研发、生产和营销。公司的主要产品是创新生物药物苏肽生（注射用鼠神经生长因子）、特色品种舒泰清（复方聚乙二醇电解质散（IV））。","listedPrice":52.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"舒泰神,300204,舒泰神股票,舒泰神股票老虎,舒泰神股票老虎国际,舒泰神行情,舒泰神股票行情,舒泰神股价,舒泰神股市,舒泰神股票价格,舒泰神股票交易,舒泰神股票购买,舒泰神股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}